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Introduction 
In early December 2019, a cluster of cases of pneumonia of unknown origin were identified 
in Wuhan, the capital city of Hubei province in China. The clinical features of the condition 
included fever, shortness of breath and pneumonic infiltrates in both lungs. [1], which were 
similar to those seen in the severe acute respiratory syndrome (SARS) epidemic that occurred 
in Asia in 2003 and the Middle Eastern Respiratory Syndrome (MERS) identified in the Arabian 
Peninsula in 2010. Nucleic acid sequencing of lower respiratory tract samples from infected 
patients identified the causative agent as a previously unidentified coronavirus [2] that has 
been termed SARS-CoV-2, to distinguish it from the virus causing the earlier SARS epidemic 
(SARS-CoV). The Wuhan outbreak was declared a Public Health Emergency of International 
Concern by the WHO on 30 January 2020 and a pandemic on 11th March. The WHO 
designated ‘Corona Virus Disease 2019’ (COVID-19) as the official name for this new disease. 
At the time of writing this editorial in May 2020, there have been approximately 5.5 million 
COVID-19 cases globally with over 344,000 COVID-19 attributed deaths [3], although it is 
widely acknowledged that these figures considerably underestimate the true scale of the 
pandemic. 
Given the rapidly expanding literature on COVID-19, it is timely to summarise what we have 
learned so far about the effects of COVID-19 on the eye and discuss the implications of the 
current pandemic for eye care practitioners. To identify the relevant source literature, we 
used a database of COVID-19 citations that are most relevant to ophthalmology, which has 
been developed by the Cochrane Eyes and Vision (CEV) US satellite. The database uses a 
machine learning classifier to screen thousands of biomedical citations indexed in PubMed to 
identify relevant reports. Records that had any matching eyes and vision terms were verified 
by an ophthalmologist. Given the short timeline since the start of the pandemic, some of the 
included studies are preliminary reports that are yet to be certified by peer review. The search 
was last updated on 30th April 2020. 
Ocular manifestations of COVID-19 
Although coronaviruses are well known pathogens of birds and mammals, only seven 
coronaviruses were known to infect humans (Human Coronavirusus (HCoV)). [4] Four of these 
(OC43, 229E, HKU1, NL63) cause approximately 15% of common colds and some cases of 
pneumonia, particularly in children and the elderly. By contrast, SARS-CoV, MERS-CoV and 
the novel SARS-CoV-2 can result in life-threatening respiratory failure. A recent review, which 
summarised ocular implications of known coronaviruses in humans and animals [5] concluded 
that, although a wide spectrum of ocular manifestations of coronaviruses have been 
documented in animals, the literature on ocular involvement in humans is sparse. However, 
a retrospective case series of 18 hospitalized children diagnosed with respiratory tract 
infections and testing positive for HCoV NL63, reported the presence of conjunctivitis as an 
associated feature in 17% of children. [6] 
At this relatively early stage of the COVID-19 pandemic, it is difficult to draw definitive 
conclusions on the prevalence of ocular involvement. There have been isolated case reports 
to suggest that conjunctivitis or keratoconjunctivitis can be the first clinical manifestation of 
the disease. [7] [8] [9] However, estimates for the prevalence of conjunctivitis in established 
COVID-19 comes predominantly from early reports from hospitalised patients in China and 
Singapore (Table 1). [10-18] The majority of studies reported on samples of <100 and in some 
reports ‘conjunctival congestion’ was used as a proxy diagnostic indicator of viral 
conjunctivitis. Based on the currently available evidence, we conclude that conjunctivitis is a 
rare complication of COVID-19, with an estimated pooled prevalence of 4% or less depending 
on the meta-analytical model used (Figure 1). 
 










Chen 2020 [10] China 534 25 No N/A 
Guan 2020 [11] China 1099 9 No N/A 
Lan 2020 [12] China 81 0 Yes 0/3 
Seah 2020 [13] Singapore 17 1 Yes 0/17 
Wu 2020 [14] China 38 12 Yes 2/28 
Xia 2020 [15] China 30 1 Yes 1/30 
Ye 2020 [16] China 30 3 Yes 5/27 
Zhang 2020 [17] China 72 2 Yes I/2 
Zhou 2020 [18] China 63 1 Yes 3/63 
 





Figure 1. Forest plot of the prevalence of presumed conjunctivitis in hospitalised patients 
with COVID-19. The Freeman-Tukey Double Arcsine Transformation was used to stabilize 
the variances prior to pooling using fixed and random effects models. 
 
All of included patients had a clinical diagnosis COVID-19 with the majority testing positive 
for SARS-CoV-2 by serology or nasopharyngeal swabs. Testing of conjunctival swabs or tear 
samples was performed on the minority of the included patients (8.7%), which confirmed 
the presence of the virus in approximately 3% of samples (Table 1, Figure 2).  
 
 
Figure 2. Forest plot of the proportion of positive tests from conjunctival swab/tear samples 
in hospitalised patients with COVID-19. 
 
 
Although there is accumulating evidence that COVID-19 predisposes patients to thrombotic 
disease that involves both the arterial and venous circulations, [19] evidence for a causal 
relationship between SARS-CoV-2 and ischaemic stroke is equivocal due to competing 
vascular risk factors in most patients. The same would apply in the case of a putative 
increased risk of retinal vascular occlusions. With regard to other retinal findings, a recently 
published case series reported bilateral OCT abnormalities in 12 patients with confirmed 
COVID-19. These included hyper-reflective lesions at the level of ganglion cell and inner 
plexiform layers of the retina, particularly within the papillomacular bundle. In four of these 
patients cotton wool spots and microhaemorrhages were also observed on fundus 
examination. All patients had normal visual acuities and pupillary reflexes. [20] 
 
Infectivity of the tears and conjunctival transmission 
In order to replicate in a host animal, viruses must first adhere to receptors on host cells.  In 
coronaviruses this is achieved via the spike proteins that protrude through their lipid 
envelopes (and which give them their familiar ‘crown-like’ ultramicroscopic appearance).  
The SARS-CoV-2 virus uses the angiotensin converting enzyme-2 (ACE2) receptors present 
on human cells to bind to them, being primed to do so by the serine protease TMPRSS2. [21] 
Current belief is that the normal human conjunctiva possesses ACE2 receptors but not the 
priming protease [22], so it should not be theoretically possible for the SARS-CoV-2 virus to 
bind to the ocular surface and hence to initiate infection.  It would however be possible for 
viruses reaching the ocular surface to be washed with the tears along the nasolacrimal ducts 
into the nasopharynx and from there to the respiratory and gastrointestinal tracts, where 
membrane-bound priming proteases are abundant, facilitating adherence. [23] In that 
sense, infection with the SARS-CoV-2 virus via the ocular surface is possible.  As to why 
coronaviruses should be found in tears, apart from direct inoculation from infected droplets 
reaching the eye surface (for example from a cough or sneeze of an infected person), there 
are the theoretical possibilities of migration from the nasopharynx via the nasolacrimal duct 
and haematological infection of the lacrimal gland. [5] Given that SARS-CoV-2 virus has been 
detected in stool samples, the possibility of faecal to hand to eye transmission also exists. 
[24] 
Conjunctival swab samples from the tears of infected individuals have proved positive for 
SARS-CoV-2 RNA, using the reverse-transcription polymerase chain reaction (RT-PCR), 
whether or not there are ocular manifestations.  Similar findings were made during the 
SARS-CoV pandemic, though it is interesting to note that neither conjunctival inflammation 
nor other ocular manifestations were reported during either the SARS-CoV or the MERS-CoV 
pandemics. [25] A recent paper concluded that the risk of SARS-CoV-2 transmission through 
tears is low. [13] 
Though it remains theoretically possible, transmission of coronavirus infection from the 
conjunctival surface of one individual to that of another, during the course of a clinical 
examination, has not so far been documented. 
Personal protective equipment and implications for ophthalmic service delivery  
On 30th December 2019 Li Wenliang, an ophthalmologist working at Wuhan Central 
Hospital, warned fellow doctors about a possible outbreak of an illness that resembled 
severe acute respiratory syndrome (SARS).  He was summoned to the Public Security Bureau 
and made to sign a document which accused him of making false statements that disturbed 
the public order.  He was, in fact, one of the first to recognise the outbreak of the novel 
coronavirus disease COVID-19.  He contracted the disease from a patient and died of the 
infection on 7th February.  His case illustrates the need for us all to speak out if we are faced 
with new and disturbing clinical situations, and reminds us that, as eye care practitioners, 
we are at personal risk in the face of emerging respiratory virus infections, of which there is 
no reason to believe that COVID-19 will be the last.  
The provision of eye care involves, at times, close physical proximity between practitioners 
and patients and this is why ophthalmologists, optometrists, orthoptists and other eye care 
workers can be considered to be at special risk of contracting infection with the SARS-CoV-2 
virus.  It is believed that the virus is transmitted in exhaled liquid droplets of 5µm diameter 
or larger, such as are generated during coughing, sneezing, singing and speaking.  
Transmission may also occur via aerosols (i.e. droplets smaller than 5µm) [26] a mechanism 
that has been established for influenza viruses (Bischoff et al 2013). [27]  It is not known 
what concentration of coronavirus particles, or the length of exposure, is necessary to 
produce an infection.  The concept of ‘viral load’ may be helpful.  It is intuitive and probably 
correct that the viral load to which a person is exposed should influence the incidence and 
severity of infection, though direct evidence is hard to obtain. [28]   Strategies to minimise 
the potential viral load should be kept constantly in mind during eye examinations.  
In addition to inoculation from droplets and aerosols, SARS-CoV-2 infection is also 
transmitted via contaminated surfaces, where the viral concentration shows an exponential 
decay, with the median half-life varying with the nature of the surface, ranging from 6.8 
hours on plastic to 5.6 hours on stainless steel, with lower values on cardboard and 
(especially) copper. [29] For this reason, instruments that come into contact with the eye 
surface, such as diagnostic lenses (gonioscopes, 3-mirror and similar lenses, pachymetry and 
ultrasound probes) should be disinfected with ethanol-based solutions, and disposable 
alternatives, such as single-use applanation tonometer tips and iCare tonometer probes, 
used whenever possible. 
Strategies to control the risk of infection in the eye clinics of two Hong Kong hospitals have 
been described by Lai and colleagues. [30] They adopted a three-level hierarchy of control 
measures: (1) Administrative control, (2) Environmental control and (3) The use of personal 
protective equipment (PPE).  Administrative control involved lowering patient attendance, 
suspending elective clinical services, patient triage and the use of patient questionnaires.  
Environmental control included fresh air access, shields and the frequent disinfection of 
surfaces that were often touched by health care workers, and video-conferencing between 
members of staff.  Eye protection equipment was provided to all ophthalmologists and 
surgical masks were worn by both ophthalmologists and patients.  Hand hygiene was 
regarded as particularly important; ophthalmologists were to practise hand hygiene using 
the WHO formula alcohol hand rub or hand washing after every patient encounter, and if 
gloves were worn, they were removed followed by hand hygiene between cases. 
The challenges special to eye care practitioners are dictated by the anatomy of the eyes, 
which are situated within a short distance of the nose and mouth, with physical connection 
between the ocular surface and the nasopharynx via the nasolacrimal duct.  Certain modes 
of examination, such as direct ophthalmoscopy, contact lens intervention and the need to 
touch the eyelids during examination can be regarded as potentially hazardous, as is the 
short inter-personal distance at the slit lamp.  Conversation at the slit lamp is not 
recommended, because of the inevitable generation of droplets and/or aerosols.  A simple 
home-made slit lamp breath shield has been described. [31] 
The College of Optometrists Guidance for Optometrists (Coronavirus (COVID-19) pandemic: 
Guidance for Optometrists)[32], last updated on 19th May 2020, is a comprehensive guide 
to working with patients at this time, and should be referred to by all practitioners.  It 
addresses issues that have been controversial, including the wearing of PPE (disposable 
aprons, gloves and surgical masks), and advises: ‘Do not deliver face-to-face care at less 
than two metres if you do not have appropriate PPE.  Instead, direct the patient to a service 
that does.’  This Guidance also recommends against the use of pneumo- (air puff) tonometry 
on the grounds that the instrument may generate aerosols which could pose a risk to eye-
care practitioners and their other patients.  This potential problem was identified many 
years ago. [33] 
A brief joint statement on viral conjunctivitis and COVID-19 by the Royal College of 
Ophthalmologists (RCOphth) and the College of Optometrists was issued on 19th March 
2020. [34] The British Contact Lens Association has also issued guidance, both for eye care 
practitioners and for consumers. [35] On 25th March, the RCOphth updated guidance to 
ophthalmologists [36], which has also been endorsed by the College of Optometrists. The 
guidance recommends that clinicians should wear standard surgical masks when examining 
or treating patients at the slit lamp and the use of plastic breath shields, which must be 
disinfected between patients, attached to slit lamps. In addition, they recommend that the 
clinician should avoid speaking at the slit lamp. Professional bodies in the USA and Australia 
have collated evidence and provided similar guidance on patient management in relation to 
COVID-19, including recommendations on the use of PPE [37, 38}. 
 
Conclusion 
The evidence base for the SARS-CoV-2 virus and COVID-19 disease is expanding at a 
phenomenal rate. We are now much better informed on all aspects of the new virus, and 
the pandemic that it has caused, than we were earlier in the year. This has led to a wider 
understanding of the risks toboth patients and practitioners of eye care procedures and how 
these risks can be minimised. We all look forward to the advent of effective anti-viral 
therapies and/or vaccines, but until they are available, it is likely that these alterations to 
our professional practice will remain in place. 
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